Core Viewpoint - DirectBooking Technology Co., Ltd. has received shareholder approval for significant changes including an increase in share capital, conditional share subdivision and consolidation, enhanced voting rights for Class B shares, and updated governing documents [1]. Increase of Share Capital - The authorized share capital will increase from US$250,000 to US$40,000,000, allowing for a total of 5,000,000,000 ordinary shares, which includes 4,900,000,000 Class A shares and 100,000,000 Class B shares [2]. Conditional Subdivision of Share Capital - A general mandate has been granted to the Board to subdivide share capital if the closing bid price exceeds US$100, with a subdivision ratio between 1:2 and 1:100 [3]. Conditional Consolidation of Share Capital - The Board is authorized to consolidate share capital if the closing bid price falls below US$1.00, with a consolidation ratio between 2:1 and 1,000:1 [4]. Amendment of Rights of Shares - The voting rights for Class B Ordinary Shares will be amended from 50 votes to 100 votes per share, effectively doubling their voting power [5]. Adoption of Updated Governing Documents - The third amended and restated memorandum and articles of association will be adopted, reflecting changes including enhanced Class B voting rights and previous share capital adjustments [6]. Consent to Share Repurchase and Issuance - Shareholders consented to the repurchase of 395,834 Class A Ordinary Shares and the issuance of an equal number of Class B Ordinary Shares to Fortiwealth Advisory Co., Ltd., converting part of their holding into high-vote shares [7]. Company Overview - DirectBooking Technology Co., Ltd. is a holding company based in the Cayman Islands, operating through its Hong Kong subsidiary, Primega Construction Engineering Co. Limited, providing transportation services in the construction industry with a focus on environmentally friendly practices [9].

Core Viewpoint - OSE Immunotherapeutics SA has corrected a processing error regarding the total number of shares and voting rights, which was identified in preparation for the upcoming General Meeting on September 30, 2025. The error does not affect the rights of beneficiaries or previously cast votes [2][3][4]. Group 1: Correction of Material Error - The total number of outstanding shares is now confirmed to be 22,463,262, with theoretical voting rights amounting to 27,859,524 [3]. - The error was due to an inaccurate legal qualification by a corporate advisor and was promptly addressed by the Board of Directors on September 23, 2025 [4]. Group 2: Response to Allegations - OSE Immunotherapeutics refutes allegations of "fraudulent manipulation" made by a group of minority shareholders, asserting that the error was unintentional and not a result of deliberate actions [4][5]. - The company expresses regret over the aggressive communication strategy adopted by certain minority shareholders, emphasizing its commitment to constructive dialogue with all shareholders [5]. Group 3: Shareholder Agreement and Voting Intentions - A group of 61 founding, historical, employee, and executive shareholders has entered into an agreement regarding the voting of resolutions at the General Meeting [6]. - This Shareholder Group now holds approximately 14.22% of the company's share capital and 19.05% of voting rights, and they intend to vote in favor of the Board of Directors' proposed resolutions while opposing those from the minority shareholders [7]. Group 4: Proxy Advisory Recommendations - Two international proxy advisory firms have recommended voting in favor of the resolutions proposed by the Board of Directors concerning its composition [8]. - The firms have differing opinions on other resolutions related to executive remuneration and financial authorizations, encouraging shareholders to review the full recommendations [9].